Three Years' Follow-up from the ATAC Trial is Sufficient to Change Clinical Practice: A Debate

[1]  James N Ingle,et al.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Buzdar.  The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) Trial in Postmenopausal Women with Early Breast Cancer – Updated Efficacy Results Based on a Median Follow-up of 47 Months , 2003, Breast Cancer Research and Treatment.

[3]  L. Fallowfield,et al.  Assessing the quality of life of postmenopausal women randomized into the ATAC (“arimidex”, tamoxifen, alone or in combination) adjuvant breast cancer trial , 2003 .

[4]  R. Sainsbury.  Beneficial side-effect profile of anastrozole compared with tamoxifen confirmed by additional 7 months of exposure data: a safety update from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial , 2002 .

[5]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.

[6]  E. Winer,et al.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Glück.  Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma Results of Two Randomized Trials Designed for Combined Analysis , 2001 .

[8]  A. Buzdar,et al.  Anastrozole is superior to tamoxifen as first‐line therapy in hormone receptor positive advanced breast carcinoma , 2001, Cancer.

[9]  R. Brueggemeier.  Aromatase, Aromatase Inhibitors, and Breast Cancer , 2001, American journal of therapeutics.

[10]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[11]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[12]  H. Mouridsen,et al.  Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R B Mazess,et al.  Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.

[14]  R. Love,et al.  Symptoms associated with tamoxifen treatment in postmenopausal women. , 1991, Archives of internal medicine.